
Court Ruling Limits Ozempic Copies in Favor of FDA, Novo Nordisk
A federal court in Texas has
The ruling, issued April 24 in the U.S. District Court for the Northern District of Texas, denied a request from the Outsourcing Facilities Association (OFA) to block the FDA's recent
That decision effectively ended a temporary allowance for pharmacies to compound semaglutide-based drugs for patients. Semaglutide is the active ingredient in Ozempic and Wegovy. Court documents remain
According to a KFF
Without the shortage designation, pharmacies may no longer produce compounded versions of semaglutide except in rare circumstances. Smaller 503A pharmacies must stop immediately, while larger outsourcing facilities have until May 22 before facing FDA enforcement.
The FDA
said in
had been in shortage since 2022 due to 'increased demand.'
Related Stories
2/24/2025
1/29/2025
Several other lawsuits regarding another popular weight loss medication called tirzepatide [brand name Zepbound and Mounjaro] are also ongoing, as its manufacturer, Eli Lilly, has taken a similar legal approach as Novo Nordisk. The FDA
In an emailed statement to The Epoch Times on Friday, the Outsourcing Facilities Association said it was 'deeply disappointed' by the court's decision.
'The U.S. District Court for the Northern District of Texas misapprehended or failed to take into consideration the clear and convincing evidence that demonstrates that the manufactured supply of semaglutide is not able to meet the enormous demand in the U.S.,' said OFA Chairman Lee H. Rosebush.
'We look forward to the opportunity to introduce this evidence again through the legal process and in discussions with the FDA. We will not stop in our efforts to ensure that patients can get access to this vital medication.'
Novo Nordisk said the ruling supports the FDA's conclusion that the supply of its brand-name semaglutide products is sufficient to meet U.S. demand.
'The court's ruling left in place FDA's prior determination that all doses of Wegovy® and Ozempic® are fully available nationwide and that Novo Nordisk's supply of these FDA-approved medicines is meeting or exceeding current and projected nationwide patient demand,' the company said in the statement.
'With the FDA's resolution of the shortage of Ozempic® and Wegovy®, as left in place by this court ruling, it is illegal under U.S. compounding laws to make or sell knockoff 'semaglutide drugs,' with rare exceptions.'
The company said it has filed 111 lawsuits in federal courts across 32 states to stop the marketing and sale of what it describes as knockoff or misbranded compounded versions.
'We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage of Wegovy® and Ozempic® is resolved,' said Steve Benz, Novo Nordisk's general counsel.
'FDA's determination was based on a thorough review of Novo Nordisk's stable and growing supply of these important FDA-approved medicines. With the end of the shortage of Wegovy® and Ozempic®, no patient should have to be exposed to unsafe, inauthentic 'semaglutide' drugs. Patient safety remains a top priority for Novo Nordisk, and the extensive nationwide legal actions we have taken to protect Americans from the health risks posed by illegitimate 'semaglutide' drugs are working.'
While brand-name drugs such as Ozempic and Wegovy can cost
Novo Nordisk says its legal efforts are aimed at protecting patients from unsafe or unregulated products, including those made with synthetic semaglutide from overseas suppliers, such as manufacturers in China that have not been reviewed by the FDA.
Novo Nordisk and the FDA did not respond to additional questions from The Epoch Times before publication time.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
FDA approves YolTech's YOLT-101 for familial hypercholesterolemia
YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for YOLT-101 to treat heterozygous familial hypercholesterolemia (HeFH). YOLT-101 is an in vivo base editing therapy designed to target proprotein convertase subtilisin/kexin type 9 (PCSK9). Its innovative approach lies in its potential to durably reduce blood low-density lipoprotein cholesterol (LDL-C) levels through a single-dose treatment. The technology behind YOLT-101 incorporates YolTech's adenine base editor, known as hpABE5, which consists of nCas and a new deaminase evolved from Hafnia paralvei. To deliver this therapeutic agent, the company employs an advanced lipid nanoparticle (LNP) delivery system. hpABE5 can perform precise A•T to G•C base conversions without inducing DNA double-strand breaks, thus minimising risks associated with chromosomal abnormalities and off-target effects. YolTech Therapeutics co-founder and CEO Yuxuan Wu stated: 'The FDA IND clearance marks a significant milestone for YolTech. In vivo gene editing represents a new generation of therapeutics — offering one-time, durable solutions for chronic and genetic diseases. 'We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases.' Currently under evaluation in an ongoing investigator-initiated trial (IIT), YOLT-101 has shown promising results with a favourable safety profile and substantial LDL-C–lowering effects. Familial hypercholesterolemia is a genetic disorder stemming from mutations affecting LDL metabolism-related genes such as LDLR, Apolipoprotein B (APOB) and PCSK9. Individuals suffering from FH typically experience elevated LDL-C levels, which contribute to a heightened risk of developing early-onset atherosclerotic cardiovascular diseases. "FDA approves YolTech's YOLT-101 for familial hypercholesterolemia" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Hanes Names S&S Activewear Exclusive Distributor for Printwear Channel
Historic agreement marks new chapter for iconic brand and long-standing partnership BOLINGBROOK, Ill., June 09, 2025--(BUSINESS WIRE)--S&S Activewear and HanesBrands Inc. are proud to announce a landmark agreement that makes S&S the exclusive distributor of the Hanes brand in the North American printwear channel. This milestone builds on a decades-long partnership and sets the stage for a bold new era of growth, innovation and customer focus. At the heart of the Hanes legacy is the iconic Beefy-T®, a style that helped define the printwear category and continues to be a customer favorite for its comfort, durability and printability. Hanes is the top-selling apparel brand in the U.S. and brings over 110 years of heritage in quality and innovation to the market. With this exclusive partnership, S&S will not only carry the full range of Hanes styles but will also offer deeper inventory positions and enhanced availability across its national distribution network—ensuring decorators and promotional partners get what they need, when they need it. "This is more than an agreement—it's an evolution of one of the industry's most enduring relationships," said Mike Faircloth, HanesBrands President Global Operations. "Hanes has been a foundational brand in printwear for decades. With S&S as our exclusive distributor, we're doubling down on that legacy while positioning ourselves to lead in the next chapter of the market." The partnership comes on the heels of S&S's successful integration with alphabroder—creating a unified platform that offers customers expanded product access, faster delivery and unmatched service. With over 6 million square feet of warehouse space, advanced automation technologies, and a portfolio of more than 100 top industry and exclusive brands, S&S has established itself as the leading technology-enabled, customer-focused distributor in the channel. "We're incredibly proud to deepen our relationship with Hanes, a brand that represents both heritage and reliability," said Frank Myers, CEO of S&S Activewear. "As a unified company, we're in a better position than ever to bring more of Hanes's trusted styles to more customers, more efficiently while continuing to raise the bar on service." Through this strategic alignment, customers can expect: A focused and expanded Hanes assortment, available exclusively from S&S Deeper inventories across S&S's nationwide network of distribution centers Faster shipping and delivery windows for Hanes styles Seamless ordering through the unified S&S website and service model Customers may continue to purchase Hanes products from other distributors through the transition period. This partnership will be fully operational by December 31, 2025. This agreement reflects a shared belief that the future of the printwear industry will be shaped by deeper, more strategic partnerships between manufacturers and distributors—focused on long-term brand building, supply chain alignment and delivering unmatched value to customers. "As we continue to grow, our focus remains on supporting the industry's most trusted brands," added Myers. "We believe strong partnerships with manufacturers like Hanes are what drive value and progress for the industry and our customers." For more information on S&S Activewear, visit For more information on Hanes, visit About S&S Activewear Founded in 1988 and headquartered in Bolingbrook, Illinois, S&S Activewear is a leading technology-enabled distributor of apparel and accessories in the United States and Canada. S&S offers more than 100 brands, including basic garments to fashion-forward styles, with over 6 million square feet of warehouse space across North America. S&S services a broad range of customers through its nationwide network, including retail brands, e-commerce companies, garment decorators, promotional products distributors, entertainment merchandisers, lifestyle brands and web-based platforms for apparel customization. About HanesBrands Hanes, America's No. 1 apparel brand, has been a trusted name in comfort and quality for over a century. As a leading provider of intimates, underwear, sleepwear, socks, and casual apparel, Hanes is committed to delivering innovative designs that prioritize fit, durability, and everyday ease. The brand is also dedicated to sustainability, with a focus on responsible sourcing, reducing environmental impact, and supporting ethical manufacturing practices. Hanes products are available at major retailers nationwide and directly at making comfort accessible to everyone. View source version on Contacts Media Contacts For S&S,Hope SanderRed Fan Communicationspr@ 737-280-8783 For Hanes,Jonathan Binder336-682-9654 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The SHIELD II trial is designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with the standard of care (SoC), which includes prophylactic systemic antibiotics, compared to the SoC alone arm in the prevention of post-abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The trial's primary endpoint is measured by the proportion of subjects with a surgical site infection or mortality for any reason within 30 days post-surgery. FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe, and Israel. D-PLEX100, PolyPid's lead product candidate, is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. The trial met the primary efficacy endpoint, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX100 plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p<0.005). SHIELD II included three key secondary endpoints: The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX100 plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p<0.005). The second key secondary endpoint showed statistical significance in favor of D-PLEX100 plus SoC over SoC alone (p<0.005). The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS1 score >20 in the D-PLEX100 plus SoC arm compared to the SoC alone arm (p<0.05). The ASEPSIS score is a clinical tool used to assess surgical wound infections objectively. The independent Data Safety Monitoring Board raised no safety concerns in SHIELD II. The company expects to submit a New Drug Application to the U.S. Food and Drug Administration in early 2026, with a Marketing Authorization Application in the E.U. to follow shortly thereafter. Price Action: PYPD stock is trading higher by 12% to $3.66 at last check Monday. Read Next:Photo by ittawit21 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.